Compare MRK & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRK | SCLXW |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.2B | N/A |
| IPO Year | N/A | N/A |
| Metric | MRK | SCLXW |
|---|---|---|
| Price | $108.43 | $0.17 |
| Analyst Decision | Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $111.93 | N/A |
| AVG Volume (30 Days) | ★ 13.9M | 4.0K |
| Earning Date | 02-03-2026 | 03-07-2025 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 58.08 | N/A |
| EPS | ★ 7.56 | N/A |
| Revenue | ★ $64,235,000,000.00 | $55,152,000.00 |
| Revenue This Year | $1.98 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $14.41 | ★ N/A |
| Revenue Growth | 1.68 | ★ 22.02 |
| 52 Week Low | $73.31 | $0.18 |
| 52 Week High | $110.17 | $0.18 |
| Indicator | MRK | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 71.12 | 55.79 |
| Support Level | $104.43 | $0.07 |
| Resistance Level | $107.59 | $0.19 |
| Average True Range (ATR) | 2.09 | 0.03 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 79.29 | 92.00 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.